Questcor hires Shire’s chief executive
pharmafile | June 11, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Questcor, Shire
Biopharma firm Questcor Pharmaceuticals has appointed the recently-retired chief executive of Shire to its Board of directors.
Angus Russell had a five-year tenure as chief executive at Shire, and prior to that he was chief financial officer at the firm for nine years. Russell joined the company in 1999 and he retired at the end of April.
“Angus is a respected biopharmaceutical industry leader with a proven track record in specialty pharmaceuticals,” said Virgil Thompson, chairman of Questcor’s Board of directors. “Over his many years at Shire, Angus spearheaded and achieved numerous initiatives and helped to transform the company into the global industry leader that it is today. We look forward to benefitting from Angus’ 32 years of experience in the speciality pharmaceutical industry as we continue to focus on the treatment of patients serious, difficult-to-treat autoimmune and inflammatory disorders.”
In addition to serving as chief executive at Shire, Russell was also the chairman of its leadership team and was previously a lead member of the Shire management committee that devised and implemented Shire’s long-term, focused business strategy.
Russell said: “I am pleased to join the Board at this exciting time and look forward to helping the company to pursue the many opportunities that lie ahead.”
Prior to joining Shire, Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as vice president of Corporate Finance at AstraZeneca. In that role he was responsible for financial input into merger and acquisition activities, management of tax, legal and finance structure, investor relations, and the management of various financial risks.
Related Content
Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …
Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …
